These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 8996130)

  • 1. Proposal for classifying the acute emetogenicity of cancer chemotherapy.
    Hesketh PJ; Kris MG; Grunberg SM; Beck T; Hainsworth JD; Harker G; Aapro MS; Gandara D; Lindley CM
    J Clin Oncol; 1997 Jan; 15(1):103-9. PubMed ID: 8996130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.
    Grunberg SM; Osoba D; Hesketh PJ; Gralla RJ; Borjeson S; Rapoport BL; du Bois A; Tonato M
    Support Care Cancer; 2005 Feb; 13(2):80-4. PubMed ID: 15599601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
    Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
    J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents.
    Jordan K; Chan A; Gralla RJ; Jahn F; Rapoport B; Warr D; Hesketh PJ
    Support Care Cancer; 2017 Jan; 25(1):271-275. PubMed ID: 27501965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
    Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline.
    Paw Cho Sing E; Robinson PD; Flank J; Holdsworth M; Thackray J; Freedman J; Gibson P; Orsey AD; Patel P; Phillips R; Portwine C; Raybin JL; Cabral S; Sung L; Dupuis LL
    Pediatr Blood Cancer; 2019 May; 66(5):e27646. PubMed ID: 30729654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute and delayed nausea and emesis control in pediatric oncology patients.
    Holdsworth MT; Raisch DW; Frost J
    Cancer; 2006 Feb; 106(4):931-40. PubMed ID: 16404740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity.
    Hesketh PJ; Gralla RJ; du Bois A; Tonato M
    Support Care Cancer; 1998 May; 6(3):221-7. PubMed ID: 9629873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.
    Hesketh PJ; Beck T; Uhlenhopp M; Kris MG; Hainsworth JD; Harker WG; Cohen JR; Lester E; Kessler JF; Griffen D
    J Clin Oncol; 1995 Aug; 13(8):2117-22. PubMed ID: 7636556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors.
    Costa AL; Abreu C; Pacheco TR; Macedo D; Sousa AR; Pulido C; Quintela A; Costa L
    Biomed Res Int; 2015; 2015():309601. PubMed ID: 26421283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients.
    Dupuis LL; Boodhan S; Sung L; Portwine C; Hain R; McCarthy P; Holdsworth M;
    Pediatr Blood Cancer; 2011 Aug; 57(2):191-8. PubMed ID: 21465637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.
    Kaizer L; Warr D; Hoskins P; Latreille J; Lofters W; Yau J; Palmer M; Zee B; Levy M; Pater J
    J Clin Oncol; 1994 May; 12(5):1050-7. PubMed ID: 8164029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice.
    Hesketh PJ
    Oncologist; 1999; 4(3):191-6. PubMed ID: 10394587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.
    Italian Group for Antiemetic Research
    N Engl J Med; 1995 Jan; 332(1):1-5. PubMed ID: 7990859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.